全基因组分析确定核因子1C为小细胞肺癌的新型转录因子及潜在治疗靶点
研究比较14株小细胞肺癌(SCLC)与10株非小细胞肺癌(NSCLC)细胞系及正常人气道小气道上皮细胞(SAEC)和诱导多能干细胞(iPSC)的转录组与DNA甲基化组,结合DNase I超敏位点测序识别SCLC开放染色质网络中占位评分最高的转录因子NFIC;敲低NFIC可损害葡萄糖代谢、降低干性并抑制SCLC细胞体内外生长,BET抑制剂可降低NFIC表达。
要点
- NFIC是在SCLC开放染色质位点占位评分最高的转录因子,此前未与SCLC关联。
- 敲低NFIC损害SCLC细胞葡萄糖代谢、降低干性并抑制体内外生长。
- BET抑制剂或敲低BRD4可显著降低SCLC细胞及PDX模型中NFIC表达。
核心结论
- NFIC是SCLC中的关键转录因子,可能是BET家族蛋白转录调控的潜在介导者。
- 全基因组染色质可及性分析有助于阐明肺致癌机制并识别肺癌治疗新靶点。
研究设计与样本
- 比较14株SCLC与10株NSCLC细胞系及正常人小气道上皮细胞(SAEC)和SAEC来源的诱导多能干细胞(iPSC)克隆的转录组与DNA甲基化组。
- 对SCLC细胞系、肺iPSC(Lu-iPSC)和SAEC进一步行DNase I超敏位点测序(DHS-seq)。
- 采用基因组足迹双变量分析量化染色质可及性变化和转录因子足迹深度。
- 用标准技术评估NFIC敲低后SCLC细胞生长、致瘤性、转录组和葡萄糖代谢变化,以及BET抑制剂处理后NFIC表达。
主要发现
- Lu-iPSC与SCLC之间观察到转录组和DNA甲基化组有相当多的共同性,但该分析对肺癌特有通路无信息。
- 将DHS-seq结果与RNA测序关联,识别出此前未与SCLC关联的网络。
- 结合足迹深度,NFIC在开放染色质位点的占位评分最高。
- 敲低NFIC损害葡萄糖代谢、降低干性并抑制SCLC细胞体外和体内生长。
- ChIP-seq分析识别出NFIC启动子区域有多个BRD4占据位点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Recent insights regarding mechanisms mediating stemness, heterogeneity, and metastatic potential of lung cancers have yet to be fully translated to effective regimens for the treatment of these malignancies. This study sought to identify novel targets for lung cancer therapy. METHODS: Transcriptomes and DNA methylomes of 14 SCLC and 10 NSCLC lines were compared with normal human small airway epithelial cells (SAECs) and induced pluripotent stem cell (iPSC) clones derived from SAEC. SCLC lines, lung iPSC (Lu-iPSC), and SAEC were further evaluated by DNase I hypersensitive site sequencing (DHS-seq). Changes in chromatin accessibility and depths of transcription factor (TF) footprints were quantified using Bivariate analysis of Genomic Footprint. Standard techniques were used to evaluate growth, tumorigenicity, and changes in transcriptomes and glucose metabolism of SCLC cells after NFIC knockdown and to evaluate NFIC expression in SCLC cells after exposure to BET inhibitors. RESULTS: Considerable commonality of transcriptomes and DNA methylomes was observed between Lu-iPSC and SCLC; however, this analysis was uninformative regarding pathways unique to lung cancer. Linking results of DHS-seq to RNA sequencing enabled identification of networks not previously associated with SCLC. When combined with footprint depth, NFIC, a transcription factor not previously associated with SCLC, had the highest score of occupancy at open chromatin sites. Knockdown of NFIC impaired glucose metabolism, decreased stemness, and inhibited growth of SCLC cells in vitro and in vivo. ChIP-seq analysis identified numerous sites occupied by BRD4 in the NFIC promoter region. Knockdown of BRD4 or treatment with Bromodomain and extra-terminal domain (BET) inhibitors (BETis) markedly reduced NFIC expression in SCLC cells and SCLC PDX models. Approximately 8% of genes down-regulated by BETi treatment were repressed by NFIC knockdown in SCLC, whereas 34% of genes repressed after NFIC knockdown were also down-regulated in SCLC cells after BETi treatment. CONCLUSIONS: NFIC is a key TF and possible mediator of transcriptional regulation by BET family proteins in SCLC. Our findings highlight the potential of genome-wide chromatin accessibility analysis for elucidating mechanisms of pulmonary carcinogenesis and identifying novel targets for lung cancer therapy.
引用
- Shukla V, Wang H, Varticovski L, et al. Genome-Wide Analysis Identifies Nuclear Factor 1C as a Novel Transcription Factor and Potential Therapeutic Target in SCLC. J Thorac Oncol. 2024. PMID: 38583771. doi:10.1016/j.jtho.2024.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。